A. Corey

1.2k total citations
30 papers, 972 citations indexed

About

A. Corey is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, A. Corey has authored 30 papers receiving a total of 972 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Pharmacology. Recurrent topics in A. Corey's work include Cell death mechanisms and regulation (12 papers), Cancer Research and Treatments (5 papers) and Pharmacogenetics and Drug Metabolism (4 papers). A. Corey is often cited by papers focused on Cell death mechanisms and regulation (12 papers), Cancer Research and Treatments (5 papers) and Pharmacogenetics and Drug Metabolism (4 papers). A. Corey collaborates with scholars based in United States, Canada and Spain. A. Corey's co-authors include Norma Lynn Fox, Wendy Halpern, Amita Patnaik, Kristin Padavic, Roger B. Cohen, Lyly Le, Sébastien J. Hotte, Amit M. Oza, Margaret von Mehren and Anthony W. Tolcher and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The American Journal of Cardiology.

In The Last Decade

A. Corey

30 papers receiving 943 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Corey United States 14 715 306 254 169 110 30 972
J B Marriott United Kingdom 18 641 0.9× 346 1.1× 348 1.4× 77 0.5× 99 0.9× 26 1.3k
Jaromir Sykora Germany 16 792 1.1× 283 0.9× 361 1.4× 178 1.1× 151 1.4× 26 1.0k
Vera Balz Germany 17 331 0.5× 364 1.2× 192 0.8× 145 0.9× 76 0.7× 38 838
Hui‐Jia Dong United States 12 468 0.7× 199 0.7× 194 0.8× 177 1.0× 154 1.4× 16 1.1k
Ines Abbate Italy 17 280 0.4× 301 1.0× 118 0.5× 214 1.3× 116 1.1× 46 844
Stacy Carl-McGrath Germany 15 417 0.6× 376 1.2× 96 0.4× 161 1.0× 46 0.4× 17 926
Kazutaka Kurokohchi Japan 20 509 0.7× 302 1.0× 226 0.9× 130 0.8× 495 4.5× 71 1.5k
Yuko Sugiyama Japan 14 244 0.3× 346 1.1× 70 0.3× 153 0.9× 96 0.9× 62 968
Zhenghong Peng United States 15 526 0.7× 238 0.8× 89 0.4× 136 0.8× 42 0.4× 38 1.0k
Tomeka Suber United States 9 700 1.0× 148 0.5× 155 0.6× 87 0.5× 177 1.6× 17 947

Countries citing papers authored by A. Corey

Since Specialization
Citations

This map shows the geographic impact of A. Corey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Corey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Corey more than expected).

Fields of papers citing papers by A. Corey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Corey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Corey. The network helps show where A. Corey may publish in the future.

Co-authorship network of co-authors of A. Corey

This figure shows the co-authorship network connecting the top 25 collaborators of A. Corey. A scholar is included among the top collaborators of A. Corey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Corey. A. Corey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rubinson, Lewis, A. Corey, & Dan Hanfling. (2017). Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy. PLoS Currents. 9. 5 indexed citations
2.
Riggs, Matthew M., James A. Rogers, Marc R. Gastonguay, et al.. (2011). Population Pharmacokinetics and Exposure‐Response of Albinterferon Alfa‐2b. The Journal of Clinical Pharmacology. 52(4). 475–486. 5 indexed citations
3.
Hotte, Sébastien J., Hal W. Hirte, Eric X. Chen, et al.. (2008). A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 14(11). 3450–3455. 163 indexed citations
4.
Plummer, Ruth, Gerhardt Attard, Simon Pacey, et al.. (2007). Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers. Clinical Cancer Research. 13(20). 6187–6194. 198 indexed citations
5.
Toothaker, Roger D., et al.. (2005). Influence of Coadministration on the Pharmacokinetics of Azimilide Dihydrochloride and Digoxin. The Journal of Clinical Pharmacology. 45(7). 773–780. 1 indexed citations
6.
Pacey, Simon, Ruth Plummer, Gerhardt Attard, et al.. (2005). Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies. Journal of Clinical Oncology. 23(16_suppl). 3055–3055. 19 indexed citations
7.
Tolcher, Anthony W., Heather A. Wakelee, Monica Mita, et al.. (2005). A phase I clinical study of HGS-ETR2, a fully-human monoclonal antibody to TRAIL-R2 in patients with advanced solid tumors. 65. 128–128. 3 indexed citations
8.
Corey, A., et al.. (2004). Effect of Mild and Moderate Hepatic Impairment on Azimilide Pharmacokinetics Following Single Dose Oral Administration. Journal of Pharmaceutical Sciences. 93(5). 1279–1286. 2 indexed citations
9.
10.
11.
Tolcher, A. W., Amita Patnaik, Eric K. Rowinsky, et al.. (2004). A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3060–3060. 10 indexed citations
12.
Bono, Johann S. de, Gerhardt Attard, Ruth Plummer, et al.. (2004). 197 A phase I and pharmacokinetic (PK) study of an agonistic, fully human monoclonal antibody, HGS-ETR2, to the TNF-alpha related apoptosis inducing ligand receptor 2 (TRAIL R2) in patients with advanced cancer. European Journal of Cancer Supplements. 2(8). 61–61. 8 indexed citations
13.
Corey, A., et al.. (2002). Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration. British Journal of Clinical Pharmacology. 54(5). 449–452. 4 indexed citations
14.
Corey, A., et al.. (2000). Comparative oral bioavailability of azimilide dihydrochloride in the fed and fasted states. British Journal of Clinical Pharmacology. 49(3). 279–282. 4 indexed citations
15.
Bramer, Steven L., et al.. (1999). Effect of Multiple Cilostazol Doses on Single Dose Lovastatin Pharmacokinetics in Healthy Volunteers. Clinical Pharmacokinetics. 37(Supplement 2). 69–77. 15 indexed citations
16.
Corey, A., et al.. (1999). Pharmacokinetics and Pharmacodynamics following Intravenous Doses of Azimilide Dihydrochloride. The Journal of Clinical Pharmacology. 39(12). 1263–1271. 10 indexed citations
17.
Corey, A., Hussein R. Al‐Khalidi, Stephen Marcello, et al.. (1999). Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. Biopharmaceutics & Drug Disposition. 20(2). 59–68. 18 indexed citations
18.
Corey, A., et al.. (1999). Azimilide Pharmacokinetics following Intravenous and Oral Administration of a Solution and Capsule Formulation. The Journal of Clinical Pharmacology. 39(12). 1272–1276. 9 indexed citations
19.
Karam, Roger, Stephen Marcello, Robert R. Brooks, A. Corey, & Alan Moore. (1998). Azimilide Dihydrochloride, a Novel Antiarrhythmic Agent. The American Journal of Cardiology. 81(6). 40D–46D. 58 indexed citations
20.
Corey, A., et al.. (1997). Effect of Age and Gender on Azimilide Pharmacokinetics After a Single Oral Dose of Azimilide Dihydrochloride. The Journal of Clinical Pharmacology. 37(10). 946–953. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J B Marriott Breakdown of academic impact, for papers by Jaromir Sykora Breakdown of academic impact, for papers by Vera Balz Breakdown of academic impact, for papers by Hui‐Jia Dong Breakdown of academic impact, for papers by Ines Abbate Breakdown of academic impact, for papers by Stacy Carl-McGrath Breakdown of academic impact, for papers by Kazutaka Kurokohchi Breakdown of academic impact, for papers by Yuko Sugiyama Breakdown of academic impact, for papers by Zhenghong Peng Breakdown of academic impact, for papers by Tomeka Suber
Rankless by CCL
2026